Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry

International Journal of Cancer

Volumn 136, Issue 5, 2015, Pages E282-E289

  Nummela, Pirjo ^a   Saarinen, Lilli ^a   Thiel, Alexandra ^a   Järvinen, Petrus ^b   Lehtonen, Rainer ^a   Lepistö, Anna ^b   Järvinen, Heikki ^b   Aaltonen, Lauri A ^a   Hautaniemi, Sampsa ^a   Ristimäki, Ari ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

BRAF; GNAS; KRAS; p53; Pseudomyxoma peritonei

Indexed keywords

APC PROTEIN; B RAF KINASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; SMAD4 PROTEIN; TUMOR MARKER;

AGED; AKT1 GENE; APC GENE; ARTICLE; BRAF GENE; CANCER GRADING; CANCER PROGNOSIS; CONTROLLED STUDY; GENE; GENE MUTATION; GENOMICS; GNAS GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; OVERALL SURVIVAL; PERITONEUM PSEUDOMYXOMA; PIK3CA GENE; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SMAD4 GENE; SOMATIC MUTATION; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; MALE; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; SURVIVAL RATE;

AGED; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MUTATION; NEOPLASM GRADING; PERITONEAL NEOPLASMS; PROGNOSIS; PSEUDOMYXOMA PERITONEI; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84918546613     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29245     Document Type: Article

References (44)

1. Smeenk RM, Van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008;34:196-201.
2. Carr NJ, Finch J, Ilesley IC, et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol 2012;65:919-23.
3. Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. Dis Colon Rectum 1987;30:772-9.
4. Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J 2009;15:196-9.
5. Järvinen P, Ristimäki A, Kantonen J, Lepistö A. Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin. Scand J Surg 2013;102:145-51.
6. Bosman FT, Carneiro F, Hruban RH, et al., eds. WHO classification of tumours of the digestive system, 4th ed. Lyon: IARC, 2010. 112-25.
7. Thiel A, Heinonen M, Kantonen J, et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch 2013;463:613-21.
8. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol 2011;29:24-6.
9. Vartiainen J, Lassus H, Lehtovirta P, et al. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma. Int J Cancer 2008;122:2125-9.
10. Benlloch S, Paya A, Alenda C, et al. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 2006;8:540-3.
11. Grady WM, Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol 2014;42:124-39.
12. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
13. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006;103:1475-9.
14. Fleming NI, Jorissen RN, Mouradov D, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res 2013;73:725-35.
15. Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol 1999;154:1849-55.
16. Shetty S, Thomas P, Ramanan B, et al. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. J Surg Res 2013;180:97-103.
17. Davison JM, Choudry HA, Pingpank JF, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol, Epub March 14, 2014. DOI:10.1038/modpathol.2014.37.
18. Sio TT, Mansfield AS, Grotz TE, et al. Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. J Hum Genet 2014;59:124-8.
19. Liu X, Mody K, De Abreu FB, et al. Molecular Profiling of Appendiceal Epithelial Tumors Using Massively Parallel Sequencing to Identify Somatic Mutations. Clin Chem 2014;60:1004-11.
20. Alakus H, Babicky ML, Ghosh P, et al. Genomewide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med 2014;6:43.
21. Zauber P, Berman E, Marotta S, et al. Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix. Scand J Gastroenterol 2011;46:869-74.
22. Nishikawa G, Sekine S, Ogawa R, et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer 2013;108:951-8.
23. Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002;13:1438-46.
24. Hokari R, Lee H, Crawley SC, et al. Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1. Am J Physiol Gastrointest Liver Physiol 2005;289:G949-59.
25. O'Connell JT, Hacker CM, Barsky SH. MUC2 is a molecular marker for pseudomyxoma peritonei. Mod Pathol 2002;15:958-72.
26. Kabbani W, Houlihan PS, Luthra R, et al. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol 2002;15:599-605.
27. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011;24:1248-53.
28. Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013;62:1676-83.
29. Boyle DP, McArt DG, Irwin G, et al. The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology 2014;65:340-52.
30. Takami H, Yoshida A, Fukushima S, et al. Revisiting TP53 mutations and immunohistochemistry - a comparative study in 157 diffuse gliomas. Brain Pathol, Epub July 18, 2014. DOI:10.1111/bpa.12173.
31. Idziaszczyk S, Wilson CH, Smith CG, et al. Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer. Cancer Genet Cytogenet 2010;202:67-9.
32. Vaughn CP, Zobell SD, Furtado LV, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011;50:307-12.
33. Neumann J, Wehweck L, Maatz S, et al. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch 2013;463:509-23.
34. Fecteau RE, Lutterbaugh J, Markowitz SD, et al. GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers. PLoS One 2014;9:e87966.
35. Lee SY, Haq F, Kim D, et al. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PLoS One 2014;9:e90459.
36. Schonleben F, Qiu W, Bruckman KC, et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett 2007;249:242-8.
37. Furukawa T, Kuboki Y, Tanji E, et al. Wholeexome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011;1:161.
38. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3:92ra66.
39. Yamaguchi H, Kuboki Y, Hatori T, et al. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant. J Pathol 2013;231:335-41.
40. Amato E, Molin MD, Mafficini A, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 2014;233:217-27.
41. Dal Molin M, Matthaei H, Wu J, et al. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg Oncol 2013;20:3802-8.
42. Schonleben F, Qiu W, Ciau NT, et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006;12:3851-5.
43. Nakata B, Yashiro M, Nishioka N, et al. Very low incidence of microsatellite instability in intraductal papillary-mucinous neoplasm of the pancreas. Int J Cancer 2002;102:655-9.
44. Luttges J, Beyser K, Pust S, et al. Pancreatic mucinous noncystic (colloid) carcinomas and intraductal papillary mucinous carcinomas are usually microsatellite stable. Mod Pathol 2003;16:537-42.